Background {#Sec1}
==========

The combination of external beam radiotherapy and intracavitary brachytherapy is considered one of the standard treatments for locally advanced uterine cervical cancer. Stage IVA cervical cancer is defined by the International Federation of Gynecology and Obstetrics (FIGO) and Union for International Cancer Control as a disease directly invading the mucosa of the bladder and/or rectum. There are limited reports on the clinical results for FIGO stage IVA cervical cancer because it represents a small subset of cervical cancer patients, with estimates only around 3.1 % \[[@CR1]\]. Three- or five-year overall survival rates for stage IVA disease were reported to be between 21 and 48 % \[[@CR2]--[@CR5]\], and their prognosis is poorer than FIGO II or III disease \[[@CR3], [@CR6]\].

On the other hand, according to previous reports in the literature, most of the stage IVA patients were diagnosed based on bladder invasion, and only 1 to 4 patients in any of the studies had rectal invasion \[[@CR2], [@CR4], [@CR5], [@CR7]\]. Therefore, the prognostic value of rectal invasion in stage IVA cervical cancer is still unclear. The objective of this study is to evaluate patient outcome and prognostic factors in stage IVA cervical cancer treated with the combination of external beam radiotherapy and intracavitary brachytherapy.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

This retrospective review was performed using the medical records of patients treated with definitive photon radiation therapy for pathologically proven primary invasive cervical cancer at the National Institute of Radiological Sciences, Chiba, Japan, between 1980 and 2010. The eligible patients for the present study were diagnosed with clinical stage IVA cervical cancer by cystoscopy or/and proctoscopy, and biopsy of the bladder or rectal growth was performed for confirmation of stage IVA disease if possible. They received definitive radiation therapy consisting of the combination of external beam radiotherapy and high-dose-rate (HDR) brachytherapy. None of the patients had undergone any surgical procedures including pelvic lymphadenectomy. Pretreatment evaluation was comprised of an assessment of the patient's history, physical and pelvic examinations by gynecologists and radiation oncologists, cervical biopsy, routine blood cell counts, chemistry profile, chest X-ray, and computed tomography (CT) scans of the abdomen and pelvis. Magnetic resonance imaging (MRI) scans of the pelvis have been performed since 1993. Median age of the patients was 70 years (range, 38--87 years). All patients were staged according to the FIGO staging system, but patients with para-aortic lymph nodes ≥ 1 cm in minimum diameter on CT images were excluded from the study, although patients with enlarged pelvic lymph nodes only were included. The criterion for pelvic lymph node enlargement was ≥ 1 cm diameter on CT images. Cervical tumor size was determined from clinical descriptions, tumor diagrams, CT images and MRI (if available), and was classified into 2 categories (≤6 cm, \> 6 cm). A total of 67 patients were admitted to this retrospective analysis. This study was approved by the Ethics Committee of Human Clinical Research of the National Institute of Radiological Sciences in March of 2015, and according to the Declaration of Helsinki in its revised version. The need for informed consent was waived by the Ethics Committee of Human Clinical Research of the National Institute of Radiological Sciences because this study was non-invasive and was based on only medical records.

Treatment {#Sec4}
---------

### Radiation therapy {#Sec5}

Patients were treated with a combination of external beam irradiation and HDR intracavitary brachytherapy or interstitial brachytherapy. External irradiation was delivered with 10 MV photons by using antero-posterior and postero-anterior parallel opposing ports or four-field technique. The common whole pelvic field borders were at the interspace of the L4--5 vertebrae superiorly, at the inferior border of the obturator foramen inferiorly, and at 1.5--2 cm lateral to the bony pelvis. After start of brachytherapy, a central shield was used in the whole pelvic fields. The fraction of external irradiation was mostly 1.8 -- 2 Gy midplane tumor-dose daily, four to five fractions weekly to the pelvic lesion. Doses to the whole pelvic fields ranged from 24.0 to 54.0 Gy (median 40.0 Gy), and doses to the total pelvis, consisting of the combined doses to the whole pelvic and central shielding fields, ranged from 44.0 to 61 Gy (median 50.0 Gy). After whole pelvic irradiation, HDR intracavitary brachytherapy by remote afterloading system using iridium-192 or cobalt-60 source was performed. Source arrangement, irradiation conditions, and dose distribution were based on the Manchester system. Point A was defined on X-ray as being 2 cm superior to the external os, and 2 cm lateral from the axis of the intrauterine tandem. HDR brachytherapy was performed at 1 fraction a week, with a standard prescribed dose to Point A of 5--7 Gy per fraction, for a total dose of 1--5 fractions (median: 4 fractions).

Chemotherapy {#Sec6}
------------

In our facility, since 2002 the treatment policy for locally advanced cervical cancer has been concurrent chemotherapy (CCRT) with a chemotherapy regimen of weekly cisplatin (40 mg/m2/week). Concurrent chemoradiotherapy was not performed in patients with insufficient renal function or age over 70 years, so 5 of 17 patients received CCRT after 2002. On the other hand, most of the patients received radiotherapy alone until 2001, and 6 of 52 patients received CCRT with a chemotherapy regimen of bleomycin or peplomycin and mitomycin C. Among all patients, 56 (84 %) were treated by radiotherapy alone and 11 (16 %) by CCRT as well.

Follow-up {#Sec7}
---------

After completion of radiotherapy, patients were followed up every 1--3 months for 2 years, and every 3 or 6 months thereafter. The procedures consisted of a physical examination, routine blood cell counts, chemistry profile, chest X-ray, and CT scan. Suspected persistent or recurrent disease was confirmed by biopsy whenever possible.

Statistical analysis {#Sec8}
--------------------

Time to recurrence was measured from the date of the start of treatment. The Kaplan-Meier method was used to derive estimates of overall survival (OS), local control (LC) and disease-free survival (DFS) rates. Prognostic values were compared by DFS because the data for this study were from 1980 to 2010, and salvage treatment after recurrence had improved during these 30 years.

Prognostic values for DFS were investigated by log-rank test. Age (≥70 years or \< 70 years), tumor size (\>6 cm or ≤ 6 cm), rectal invasion (yes or no), bladder invasion (yes or no), parametrium invasion (to pelvic wall or not), vaginal invasion (lower third or not), hydronephrosis (yes or no), pelvic lymph node enlargement (yes or no), concurrent chemotherapy (yes or no), histological type (squamous cell carcinoma or adenocarcinoma) were considered binary variables. Log-rank test was used for statistical analyses of the differences of DFS, LC and OS between the patients with and without rectal invasion. Statistical significance was defined as a *P* value of \< 0.05. All statistical analyses were performed using SPSS Statistics version 18.0 (SAS Institute, Tokyo, Japan).

Results and discussion {#Sec9}
======================

Sixty-seven patients with stage IVA were diagnosed and given definitive radiation therapy during this 30-year period at our institution. Patient characteristics are presented in Table [1](#Tab1){ref-type="table"}. Fifty-three patients were stage IVA on the basis of bladder invasion, seven on the basis of rectal mucosal invasion, and seven on the basis of both bladder and rectal mucosal invasion. The median follow-up duration for all patients and surviving patients was 19 months (range, 2--235 months) and 114 months (range, 14--223 months), respectively. Median duration of treatment was 49 days (range, 25 -- 59 days). That in patients with and without rectal invasion was 49 days (range, 25 -- 59 days) and 49 days (range, 30 -- 57 days), respectively. Median total dose of external beam irradiation and HDR brachytherapy with and without central shielding fields along with BED was 91.8 Gy~10~ (range, 68.3 -- 117.1 Gy~10~) and 74.4 Gy~10~ (range, 56.3 -- 105.1 Gy~10~), respectively. That without central shielding fields in patients with and without rectal invasion was 74.4 Gy~10~, (range, 45.3 -- 105.1 Gy~10~) and 76.1 Gy~10~, (range, 56.3 -- 90.6 Gy~10~), respectively.Table 1Patient and disease characteristics (*n* = 67)CharacteristicsNo.Age, y, median (range)70 (38--87)Bladder or rectal invasion Bladder only53 (79.1 %) Rectal only7 (10.4 %) Both bladder and rectal7 (10.4 %)Parametrium invasion To pelvic wall59 (88.1 %) Not to pelvic wall8 (11.9 %)Vaginal invasion To lower third20 (29.9 %) Not to lower third47 (70.1 %)Hydronephrosis Yes32 (47.8 %) No35 (52.2 %)Pelvic lymph node enlargement Yes27 (40.3 %) No40 (59.7 %)Concurrent chemotherapy Yes (CCRT)11 (16.4 %) No (radiation therapy alone)56 (83.6 %)Histology Squamous cell carcinoma61 (91.0 %) Adenocarcinoma6 (9.0 %)Tumor size ≤6 cm22 (32.8 %) \>6 cm45 (67.2 %)

The LC, DFS and OS curves of all patients are shown in Fig. [1](#Fig1){ref-type="fig"}. The 5-year LC, DFS, and OS rates were 55, 17, and 24 %, respectively, and the 2-year LC, DFS, and OS rates were 55, 19, and 35 %, respectively. A comparison of prognostic factors for DFS in stage IVA cervical cancer patients is shown in Table [2](#Tab2){ref-type="table"}. Rectal invasion, vaginal invasion, hydronephrosis and pelvic lymph node enlargement showed statistically significant consequences on DFS, while bladder invasion had an opposite effect (Table [2](#Tab2){ref-type="table"}). The patient characteristics with and without rectal invasion are shown in Table [3](#Tab3){ref-type="table"}. The patient group with rectal invasion had a significantly higher rate of lymph node enlargement.Fig. 1Disease-free survival, local control and overall survival curves; disease-free survival (green line), local control (blue line), and overall survival curves (red line) are shown for all patientsTable 2Comparison of prognostic factors for disease-free survival in stage IVA cervical cancer patientsPrognostic factorNMedian DFS (mo)2-year DFS rate (%)*P* valueRectal invasion Yes143.600.00006 No5313.323.6Bladder invasion Yes6011.020.90.005 No73.40Parametrium invasion To pelvic wall5911.016.00.957 Not to pelvic wall82.437.5Vaginal invasion To pelvic wall205.010.00.025 Not to pelvic wall4712.722.4Hydronephrosis Yes329.07.10.033 No3511.028.6Pelvic lymph node enlargement Yes277.111.10.036 No4013.323.7Concurrent chemotherapy Yes118.79.10.272 No5610.820.6Histological type Squamous cell carcinoma6111.017.20.726 Adenocarcinoma62.633.3Tumor size ≤6 cm226.527.30.689 \>6 cm4511.014.2Table 3Patient characteristics with and without rectal invasionCharacteristicsRectal invasionNo rectal invasion (Bladder invasion only)*P* value(*N* = 14)(*N* = 53)Age, y, median (range)69 (38--80)71 (38--87)0.277Bladder invasion Yes7 (50 %)53 (100 %)0.000001 No7 (50 %)0Parametrium invasion To pelvic wall14 (100 %)45 (84.9 %)0.278 Not to pelvic wall08 (15.1 %)Vaginal invasion To lower third6 (42.9 %)14 (26.4 %)0.386 Not to lower third8 (57.1 %)39 (73.6 %)Hydronephrosis Yes7 (50 %)25 (47.2 %)0.911 No7 (50 %)28 (52.8 %)Pelvic lymph node enlargement Yes10 (71.4 %)17 (32.1 %)0.018 No4 (28.6 %)36 (67.9 %)Concurrent chemotherapy Yes (CCRT)1 (8.3 %)10 (18.9 %)0.517 No (radiation therapy alone)13 (91.7 %)43 (81.1 %)Histology Squamous cell carcinoma2 (14.3 %)4 (7.5 %)0.796 Adenocarcinoma12 (85.7 %)49 (92.5 %)Tumor size ≤6 cm2 (14.3 %)20 (37.7 %)0.180 \>6 cm12 (85.7 %)33 (62.3 %)

DFS, LC and OS curves of the patients with and without rectal invasion are shown in Figs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}, respectively. All patients without rectal invasion had bladder invasion. There were significant differences of DFS, LC, and OS among the groups (*p* = 0.00006, 0.006 and 0.05, respectively). The 2-year DFS, LC, and OS rates of the patients without rectal invasion were 24, 61, and 39 %, respectively. Those of the patients with rectal invasion were 0, 32, and 21 %, respectively. No patient with rectal invasion survived over 4 years.Fig. 2Disease-free survival curves of patients with and without rectal invasion; those of patients with rectal invasion (red line) and without rectal invasion (blue line) are shownFig. 3Local control curves of patients with and without rectal invasion; those of patients with rectal invasion (red line) and without rectal invasion (blue line) are shownFig. 4Overall survival curves of patients with and without rectal invasion; those of patients with rectal invasion (red line) and without rectal invasion (blue line) are shown

The numbers of observed Grade 2 or higher late complications are listed in Table [4](#Tab4){ref-type="table"}. Seven of 67 patients showed late complications of the bladder, 3 of the rectosigmoid colon, and 3 of the small intestine. One patient developed excised perforated intestine or sigmoid colon and vesicovaginal fistula and one patient developed vesicovaginal fistula.Table 4Grade 2 or higher late complications by RTOG/EORTC scoring schemeNo.G2G3G4-5Rect/Sigmoid67111Bladder67412Small intestine67111

Discussion {#Sec10}
----------

To the best of our knowledge, this is the first report of the analysis of the prognostic value of rectal invasion. The present study revealed that rectal invasion might be a worse prognostic factor than bladder invasion in Stage IVA cervical cancer after radiation therapy. Rectal invasion, vaginal invasion, hydronephrosis and pelvic lymph node enlargement showed statistically significant effects on DFS in these patients.

Rectal invasion might be a worse prognostic factor than bladder invasion in Stage IVA cervical cancer after radiation therapy. Several researchers reported that the 3-year or 5-year overall survival rates for stage IVA disease were between 21 and 48 % \[[@CR2]--[@CR5]\], although those studies each included only 1 to 4 patients with rectal invasion. In the present study, the 5-year survival rate of patients without rectal invasion was 30 %, a result similar to other reports. However, no patient with rectal invasion survived over 4 years, and rectal invasion showed a significant impact on DFS, as opposed to bladder invasion. DFS differed significantly between patients with and without rectal invasion (*p* = 0.0008). Thus, in Stage IVA cervical cancer, rectal invasion appears to be a poorer prognostic factor than bladder invasion.

Rose et al. and Logsdon et al. reported the significance of hydronephrosis on the outcome of patients with stage IIIB cervical cancer treated with radiation therapy \[[@CR8], [@CR9]\]. Cervical cancer extending to the lower third of the vagina has been considered as a factor involved in treatment failure. Kavadi et al. reported that the 5-year survival rate of patients with lower-third vaginal involvement in patients with stage IIIB cervical cancer was only 25 % \[[@CR10]\]. Logsdon et al. also reported that poor disease-specific survival was correlated with involvement of the lower third of the vagina \[[@CR9]\]. These reports concluded that hydronephrosis and involvement of the lower third of the vagina were poor prognostic factors in patients with stage IIIB cervical cancer. In addition, it is well known that pelvic lymph node enlargement is one of the significant prognostic factors in cervical cancer patients \[[@CR11], [@CR12]\]. In the present study, hydronephrosis, involvement of the lower third of the vagina, and pelvic lymph node enlargement showed statistically significant consequences for DFS. Thus, these factors will be poor prognostic factors in patients with stage IVA cervical cancer.

In the current study, 31 % of the patients with bladder invasion and without rectal invasion showed 5 years or longer survival, but no patients with rectal invasion reached 4-year survival, as they all developed local or/and distant failure within 18 months. Therefore, concurrent or adjuvant chemotherapy will be expected to improve the treatment outcome for such patients. Since 2001, on the basis of several randomized trials, the standard treatment for locally advanced cervical cancer, including stage IVA patients, has been CCRT \[[@CR13]--[@CR16]\]. However, there were no significant differences in DFS between patients receiving CCRT and radiation therapy alone in this study. This was obviously related to the fact that only 16 % of the patients received CCRT, as this analysis included the patients before 2000, half of the patients were elderly (median age was 70 years), and many patients had insufficient renal function due to hydronephrosis. Therefore, new treatment techniques, such as intensity-modulated radiation therapy \[[@CR17]\], image-guided brachytherapy \[[@CR18], [@CR19]\] and carbon ion radiotherapy \[[@CR20], [@CR21]\], are expected to improve the treatment outcome of stage IVA cervical cancer.

Conclusions {#Sec11}
===========

The 5-year survival rate of patients with stage IVA disease was only 24 %, so the prognosis was poor. Furthermore, for this group of patients, rectal invasion with or without bladder invasion was a worse prognostic factor than bladder invasion alone in stage IVA. Thus, these patients are in need of even more aggressive therapy.
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